Overview

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

Status:
RECRUITING
Trial end date:
2027-12-15
Target enrollment:
Participant gender:
Summary
Study on the therapeutic effect of different infusion times on tislelizumab in high-risk postoperative hepatocellular carcinoma
Phase:
NA
Details
Lead Sponsor:
Sir Run Run Shaw Hospital
Treatments:
Infusions, Intravenous
tislelizumab